New Mexico's 2025 law creating a licensed medical psilocybin therapy program under physician oversight — the first state to adopt an explicitly medical model.
New Mexico SB 219, the Medical Psilocybin Act, created a state-licensed program for psilocybin-assisted therapy under physician and clinician oversight. Governor Michelle Lujan Grisham signed it on April 7, 2025, making New Mexico the third US state with a legal psilocybin program — and the first to pass one through the legislature rather than a ballot measure.
The law does not decriminalize psilocybin for personal use. It does not allow retail sales. It creates a narrow, medically supervised pathway for patients with specific diagnoses to receive psilocybin therapy in a licensed clinical setting.
The bill passed with strong bipartisan margins: 56–8 in the House and 33–4 in the Senate. The New Mexico Department of Health (NMDOH) is the administering agency, operating through its Center for Medical Cannabis and Psilocybin.
Oregon and Colorado run wellness programs: any adult can walk in, no diagnosis needed. New Mexico took a different approach. Patients must have a qualifying diagnosis, and only licensed health care providers — not lay facilitators — can administer sessions. This places SB 219 closer to a prescription drug program than a wellness service.
That distinction shapes everything: who can access the program, who can work in it, how insurance may eventually treat it, and how the FDA might view a state precedent if federal scheduling ever changes. See our full comparison in the Oregon and Colorado section below.
SB 219 limits access to patients with one of four qualifying conditions: major treatment-resistant depression, post-traumatic stress disorder (PTSD), substance use disorders, and end-of-life care (including anxiety associated with a terminal diagnosis).
"Treatment-resistant" is significant language. It means patients must typically have tried and failed standard treatments — such as at least two antidepressants — before qualifying for major depressive disorder. The specific clinical threshold will be set by NMDOH rulemaking.
The law also gives the Department of Health power to add new qualifying conditions through rulemaking. Advocates expect conditions such as chronic pain, eating disorders, and OCD to be proposed once the advisory board completes its initial clinical framework.
Psilocybin therapy in New Mexico can only be administered by a licensed New Mexico health care provider who also holds a state psilocybin permit issued by the Department of Health. This two-requirement structure sets SB 219 apart from every other US psilocybin law.
Oregon and Colorado allow trained lay facilitators — people without clinical licenses — to supervise sessions. New Mexico requires an underlying professional license (physician, nurse practitioner, licensed therapist, or similar) plus the psilocybin-specific permit. Both must be current and valid.
Providers must also complete state-approved psilocybin training before receiving their permit. The Medical Psilocybin Advisory Board is designing those training standards during the 2025–2026 rulemaking period. For context on the range of provider paths in other states, see our guide on how to become a psychedelic therapist.
Sessions must take place in an approved clinical setting — not a private home, not a wellness retreat. NMDOH will license and inspect these facilities. Producers who cultivate or prepare psilocybin will also need a separate state permit, subject to the same regulatory framework.
One non-obvious detail: the law does not cap the number of permits in any category. Oregon started with very few licensed service centers, which created long wait times in year one. New Mexico has not built in the same bottleneck — how quickly access scales will depend on how many providers pursue training and permitting once rules are finalized.
A standard psilocybin therapy course under SB 219 has three required components: a preparation session, a dosing session, and a follow-up integration session. All three must be with a permitted provider in an approved setting.
The preparation session screens the patient's medical history, confirms the qualifying diagnosis, reviews medications for dangerous interactions (particularly MAOIs and lithium), and sets the therapeutic intention for the experience. This is more clinically rigorous than the prep session at most Oregon or Colorado centers.
The dosing session itself can run four to six hours or longer. The provider stays present throughout. The integration session afterward helps the patient make sense of the experience and connect it to their treatment goals. Integration is not optional under the medical model — it is part of the clinical protocol.
New Mexico's medical model, Oregon's wellness model, and Colorado's healing-center model all create legal supervised psilocybin access — but they differ on nearly every design choice. The table below compares the three programs across the features that matter most to patients and providers.
| Feature | New Mexico (SB 219) | Oregon (Measure 109) | Colorado (Prop 122) |
|---|---|---|---|
| Who can access | Patients with a qualifying diagnosis only | Any adult 21+ (no diagnosis needed) | Any adult 21+ (no diagnosis needed) |
| Provider requirement | Licensed health care provider + state psilocybin permit | Trained lay facilitator (no clinical license required) | Trained lay facilitator (no clinical license required) |
| Personal possession | Not decriminalized | Not decriminalized statewide | Decriminalized for adults 21+ |
| Home cultivation | Not allowed | Not allowed | Allowed for personal use |
| Authorized by | State legislature (SB 219) | Ballot measure (Measure 109, 2020) | Ballot measure (Prop 122, 2022) |
| Regulatory agency | NM Department of Health | OR Health Authority | CO Dept. of Regulatory Agencies (DORA) |
| Public equity fund | Yes — $630,000 (2026) | No | No |
| Sessions open to public | Targeted December 2026 | Yes (since 2023) | Yes (since 2025) |
When New Mexico fits better: if you have a qualifying diagnosis and want clinical oversight built into every step, or if your provider may eventually bill insurance (insurance coverage remains unlikely while psilocybin is federally Schedule I, but the medical framework positions New Mexico best for that future).
When Oregon fits better: if you want access now, if you do not have a qualifying diagnosis, or if you want the largest existing network of licensed providers. See the Oregon Measure 109 guide for current service center options.
When Colorado fits better: if you also want the option to grow your own or possess psilocybin without state criminal exposure. See the Colorado Proposition 122 guide for how the healing-center model works.
New Mexico is moving faster than its own law requires. The NMDOH received far more interest from providers and patients than it anticipated, which pushed the Advisory Board to accelerate its work. For the latest rulemaking documents, check the NMDOH Medical Psilocybin Program page directly.
Track legislative updates in all US states with The Psychedelic Journal's psychedelic legalization tracker.
New Mexico set a global precedent in 2026 by allocating public funds to pay for psilocybin therapy for patients who cannot afford it. The $630,000 Psilocybin Treatment Equity Fund, appropriated during the 2026 legislative session, is the first time any government has directly subsidized psychedelic treatment access.
Oregon and Colorado both built for-profit or nonprofit service models but allocated no public money to close the access gap. In Oregon, session costs typically range from $1,500 to $3,500 — a barrier that left the program's first year skewed toward wealthier clients. New Mexico's fund targets exactly that gap.
The fund also reflects New Mexico's broader rationale for using legislation rather than a ballot measure. The legislature treated psilocybin therapy as a public health investment — something that can receive direct budget line items — rather than a self-funding regulatory experiment left to market pricing.
Psilocybin remains a Schedule I controlled substance under the federal Controlled Substances Act. New Mexico SB 219 is state law only. It does not change federal status, and federal agents retain jurisdiction — though federal enforcement has not targeted any state psilocybin program to date.
Because psilocybin is federally Schedule I, health insurers will not reimburse sessions even under New Mexico's medical model. Patients will pay out of pocket unless they qualify for the Treatment Equity Fund or the program negotiates with Medicaid after launch. This remains the biggest practical barrier to equitable access even under the most clinically structured state model.
For a full picture of where psilocybin stands across all 50 states, see our guide to where magic mushrooms are legal and the legal status by state tool. For the federal legislative picture, see the Controlled Substances Act explainer.
Psilocybin is not legal for general use in New Mexico. SB 219, signed in April 2025, created a licensed medical program where patients with qualifying conditions — treatment-resistant depression, PTSD, substance use disorders, or end-of-life anxiety — can receive psilocybin therapy from a licensed provider in an approved clinical setting. Recreational use remains illegal under state and federal law.
SB 219 lists four qualifying conditions: major treatment-resistant depression, PTSD, substance use disorders, and end-of-life care (including anxiety related to a terminal diagnosis). The New Mexico Department of Health can approve additional conditions through rulemaking after the program launches.
The law took effect June 20, 2025. The New Mexico Department of Health is developing rules and licensing standards, with the Medical Psilocybin Advisory Board targeting first patient access by December 2026 — a year earlier than the law's hard deadline of December 31, 2027.
Oregon's Measure 109 is a wellness model: any adult 21 or older can book a supervised session at a licensed service center, no diagnosis required. New Mexico's SB 219 is a medical model: you must have a qualifying condition and a licensed clinician's authorization to participate. New Mexico also passed its program through the legislature, not a ballot measure.
Not a prescription in the traditional sense, but you do need authorization from a licensed New Mexico health care provider who holds a state psilocybin permit. That provider must confirm you have a qualifying condition before you can enter the program.
Yes. During the 2026 legislative session New Mexico allocated $630,000 to a Psilocybin Treatment Equity Fund created under SB 219. This fund is designed to reduce cost barriers for patients who cannot afford therapy. It is the first government-funded psychedelic treatment equity program in the world.
Colorado's Proposition 122 is open to any adult 21 or older with no diagnosis required, uses lay facilitators (not licensed clinicians), and also decriminalizes personal possession of psilocybin. New Mexico's SB 219 is restricted to patients with qualifying medical conditions, requires licensed health care providers, and does not decriminalize possession.
The New Mexico Department of Health (NMDOH) administers the program through its Center for Medical Cannabis and Psilocybin. A Medical Psilocybin Advisory Board convened in late 2025 shapes clinical standards, training requirements, and licensing structures, then recommends regulations to the Department.
Our booking checklist walks you through verifying a provider's license, reviewing your medications for interactions, and preparing for your preparation, dosing, and integration sessions.
→ Legal psilocybin booking checklist · Check legal status by state
Get New Mexico Medical Psilocybin Act (SB 219) updates
New votes, rules, court rulings, and access changes for New Mexico Medical Psilocybin Act (SB 219) — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.